Mānuka Performance is an advanced nutrition ingredient manufacturer — we take raw New Zealand honey and its by-product, bee dross, and turn them into validated, science-backed bioactive ingredients, consumer products, and licensable IP. We are not a honey brand. We are a bioactive science company that happens to use New Zealand honey as its primary substrate.
Our business runs across four connected pillars — consumer products, B2B ingredient supply, clinical R&D, and a bioactive data & IP platform — anchored by our own validation standard, MPS PolySure™, and manufactured toward pharmaceutical-grade (GMP) standard from Auckland.
We take two overlooked, low-value raw inputs — honey and bee dross, its waste by-product — and move both up the value curve through validated processing stages, converging into a single family of high-value products and ingredients.
Each pillar can generate revenue on its own. Together, they reinforce each other — consumer revenue funds R&D, R&D produces defensible claims and data, and that data unlocks higher-margin B2B and licensing revenue.
GI-PRO™ and LiquidFuel™ — sold direct to consumers via Amazon, D2C, and retail. This is our most visible revenue line and our proof-of-market: it generates first-party sales data, brand equity, and real-world usage evidence that strengthens every other pillar.
Bulk and formulated ingredient supply to manufacturers, brands, and food-service operators — from 3kg dispense formats for cafés and events, through to contracted bulk supply for other nutraceutical and CPG companies. Higher margin, recurring, and contract-based.
Ethics-approved trials, polyphenol validation science, and novel compound research don't generate direct revenue today — they generate the evidence that makes every other pillar more valuable. Every clinical result becomes a defensible label claim, a B2B credential, and a data asset.
Our accumulated PolySure™ dataset, provenance mapping, and screening science becomes licensable IP in its own right — to industry, regulators, and research partners. This is the layer that turns a commodity ingredient business into a data and IP platform.
Our advantage isn't a brand story — it's structural. It sits in the science, the provenance, and the formulations, and it deepens every year through ongoing research.
This moat compounds through ongoing work: an active RCT on gut microbiome outcomes, an MPI-funded polyphenol validation programme covering 100+ honey varieties, and an untargeted screening programme that has already identified ten putative novel compounds across 112 honey samples — candidates for future characterisation, reference standards, and patent-protectable IP. Every study adds another layer that a competitor without our data, our partnerships, and our provenance simply cannot replicate.
High-level Total Addressable Market (TAM), Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM) figures across our three priority export markets — conservative, bottom-up modelling built against current resourcing, not aspirational demand.
| Market | Category TAM | SAM (addressable) | SOM — Year 1 | SOM — Year 3 |
|---|---|---|---|---|
| USA | $40B–$80B | ~$3.2B–$4.8B | $1.5M | $12.6M |
| South Korea | $0.7B–$6.9B | ~$95M–$550M | $0.2M | $0.7M |
| China | $2.7B–$26.6B | ~$310M–$1.9B | $0.5M | $3.7M |
| Combined | — | — | $2.2M | $17.0M |
USA spans the sports-energy/recovery category ($40B) and the broader nutraceuticals/functional-food category ($80B, including the emerging GLP-1 adjunct-nutrition segment). Korea spans sports/endurance ($0.7B) and the wider East Asian nutraceutical category ($6.9B). China spans CBEC-addressable wellness ($2.7B) and the broader nutraceutical category ($26.6B). SOM figures assume today's headcount, budgets, and manufacturing capacity — the binding constraint on growth is capital and production capacity, not market size or product readiness.
We are consolidating manufacturing and commercial infrastructure from the Bay of Plenty into Auckland — New Zealand's largest economic centre and most connected international gateway — building toward pharmaceutical-grade (GMP) production.
To be clear on positioning: MPS PolySure™ is not an open-access standard for the wider industry. It is our proprietary validation framework, and any future availability to other honey sector participants would be structured as a licensed, revenue-generating service — another expression of Pillar 4, not a shared public good.
Phase 1 is underway within current resourcing. Phases 2 through 4 — GMP facility build, full production scale-up, and the innovation centre — are contingent on the capital raise described below; timing and sequencing will flex to the pace of funding secured.
New Zealand's honey industry exports over $400 million a year — almost entirely graded on a single antimicrobial marker (MGO). We're building the science and commercial infrastructure to change that permanently, for the whole sector, not just for us.
Our R&D programme is deliberately structured to move up the evidence ladder over time — from consumer nutrition claims today, toward the kind of clinical and mechanistic evidence that opens biotech, biomedical, and longer-range drug-development pathways.
This is a deliberate sequencing choice, not a promise of a therapeutic outcome: consumer revenue funds the science, the science funds deeper characterisation, and deeper characterisation is what eventually makes a biomedical or pharma conversation possible — on a timeline measured in years, not quarters.
We are raising USD $10M in growth capital, structured as a direct investment through the Active Investor Plus (Invest NZ) Growth Category. This capital removes the single biggest constraint on everything shown above: every forecast in this document — the SOM figures, the manufacturing phases, the market activity — is a conservative, status-quo estimate, built against today's headcount, today's budgets, and today's production capacity. It is not a ceiling on what this platform can do. It is what we can do without this capital.
Because the platform generates value in more than one way — product, ingredient supply, and IP — it also supports more than one exit pathway.